Abstract
Botulinum toxin has long been known for its paralytic effects on the human voluntary musculature via inhibition of acetylcholine release at neuromuscular junctions. Its original clinical use for the treatment of strabismus has expanded significantly to include neurological conditions related to muscle hyperactivity and/or spasticity (e.g., dystonia, spasticity, tics, tremor, dysphonia). Recently, botulinum toxin has been shown to impact autonomic disorders by acting at acceptors on glands and smooth muscle, and consequently it has been used in the management of a number of other conditions including hypersecretory disorders, pain syndromes, detrusor sphinchter dyssenergia or overactivity and gastointestinal smooth muscle/sphincter spasm; it may also reduce pain in patients for whom it is used to treat these and other primary conditions. This article will review the pharmacology and formulations of botulinum toxins as well as data from clinical trials demonstrating their efficacy for numerous conditions based on their effects on cholinergic synapses outside the motor nervous system.
Current Pharmaceutical Design
Title: Current Clinical Applications of Botulinum Toxin
Volume: 15 Issue: 31
Author(s): Daniel D. Truong, Andrea Stenner and Gerhard Reichel
Affiliation:
Abstract: Botulinum toxin has long been known for its paralytic effects on the human voluntary musculature via inhibition of acetylcholine release at neuromuscular junctions. Its original clinical use for the treatment of strabismus has expanded significantly to include neurological conditions related to muscle hyperactivity and/or spasticity (e.g., dystonia, spasticity, tics, tremor, dysphonia). Recently, botulinum toxin has been shown to impact autonomic disorders by acting at acceptors on glands and smooth muscle, and consequently it has been used in the management of a number of other conditions including hypersecretory disorders, pain syndromes, detrusor sphinchter dyssenergia or overactivity and gastointestinal smooth muscle/sphincter spasm; it may also reduce pain in patients for whom it is used to treat these and other primary conditions. This article will review the pharmacology and formulations of botulinum toxins as well as data from clinical trials demonstrating their efficacy for numerous conditions based on their effects on cholinergic synapses outside the motor nervous system.
Export Options
About this article
Cite this article as:
Truong D. Daniel, Stenner Andrea and Reichel Gerhard, Current Clinical Applications of Botulinum Toxin, Current Pharmaceutical Design 2009; 15 (31) . https://dx.doi.org/10.2174/138161209789271843
DOI https://dx.doi.org/10.2174/138161209789271843 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Steroid Regulation of Drug-Metabolizing Cytochromes P450
Current Drug Metabolism GLUT4 Associated Proteins as Therapeutic Targets for Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Application of Spray-drying and Electrospraying/Electospinning for Poorly Watersoluble Drugs: A Particle Engineering Approach
Current Pharmaceutical Design Achilles Tendon in Diabetes
Current Diabetes Reviews New Insights in Congenital Diaphragmatic Hernia
Current Respiratory Medicine Reviews Emergence of Sexual Dreams and Emission Following Deep Transcranial Magnetic Stimulation over the Medial Prefrontal and Cingulate Cortices
CNS & Neurological Disorders - Drug Targets Blood-brain Barrier Drug Discovery for Central Nervous System Infections
Current Drug Targets - Infectious Disorders The Role of Diet Related Short-Chain Fatty Acids in Colorectal Cancer Metabolism and Survival: Prevention and Therapeutic Implications
Current Medicinal Chemistry The 5-HT1B Receptor: A Novel Target for the Pathophysiology of Depression
Current Drug Targets Synthetic Glucocorticoids: Antenatal Administration and Long-term Implications
Current Pharmaceutical Design Investigations of Malignant Mesothelioma
Current Respiratory Medicine Reviews Molecular Mechanisms of Fluoroquinolone Resistance in Klebsiella
Current Drug Targets - Infectious Disorders Peptide Prodrugs for the Treatment of CNS Disorders: A Perspective for New Drugs
Current Medicinal Chemistry Is alpha-Synuclein Pathology a Target for Treatment of Neurodegenerative Disorders?
Current Alzheimer Research Commentary (Changes of Synaptic Plasticity in Multiple Sclerosis)
CNS & Neurological Disorders - Drug Targets Anterior Labial Alveolar Bone Thickness after Orthodontic Retraction of Anterior Teeth
Current Dentistry Infants and Children with Tachycardia: Natural History and Drug Administration
Current Pharmaceutical Design Neuroimaging Studies of Substance Abuse in Schizophrenia
Current Psychiatry Reviews Defective HIF Signaling Pathway and Brain Response to Hypoxia in Neurodegenerative Diseases: Not an “Iffy” Question!
Current Pharmaceutical Design Analytical Tools for Detecting Amyloid Beta Oligomerisation and Assembly
Current Pharmaceutical Analysis